Overview: AI tools are now capable of drafting complex scientific papers, sparking ethical debates.The main concerns include ...

If you are like many investors trying to decide whether Boston Scientific belongs in your portfolio right now, you are not alone. There is plenty of buzz swirling around medtech stocks this year, but ...

Experts date the beginning of the tech boom to somewhere in the 1990s. We've been living with microchips, laptops, and ...

The data center processors market is poised for growth, driven by the demand for AI capabilities, cloud services, and edge ...

For years a race-based medical calculation delayed Black patients access to life-saving kidney transplants By Anissa Durham ...

Today (13 October) is International Sceptics Day and that means we're on the case to debunk some common misconceptions that ...

Rothschild views Agilent as a leading pure play in life science instruments with diverse end markets (only 34% of revenue from Pharma) and an impressive 64% recurring revenue.